page contents
 

Home / All About Herbs / About Butterbur Monograph

 
butterbur

© 2018 Steven Foster

A butterbur monograph for the home

Latin Name: Petasites hybridus (also known as Petasites officinalis or Tussilago hybrida)


Common Names: butterbur, petasites, purple butterbur. There are also several standardized butterbur extracts, such as Petadolex


This butterbur monograph provides basic information about butterbur—common names, usefulness and safety, and resources for more information.

Source: https://nccih.nih.gov/

Butterbur Basics

  • Butterbur is a shrub that grows in Europe and parts of Asia and North America, typically in wet, marshy ground. The name, butterbur, is attributed to the traditional use of its large leaves to wrap butter in warm weather.
  • In the Middle Ages, butterbur was used for plague and fever, and in the 17th century it was used to treat cough, asthma, and skin wounds. More recently, it has been used for urinary tract symptoms, stomach upset, headaches including migraines, allergic rhinitis (hay fever), and other conditions.
  • Commercial butterbur products that contain extracts from the root, rhizome (underground stem), or leaves of the plant are available. Raw, unprocessed butterbur products, such as teas, should not be used because they contain harmful substances.

Butterbur in Health Research

  • There have been a few studies of butterbur for migraines and allergic rhinitis (hay fever) in people, so we have some knowledge of its effects on these two conditions.

Butterbur Research Summary

  • Based on two high-quality studies, the American Academy of Neurology and the American Headache Society have endorsed the use of a butterbur extract made from underground parts of the plant, like the root or rhizome, to reduce the frequency of migraines.
  • Some studies of butterbur root or leaf extracts suggest that they may be helpful for symptoms of hay fever (allergic rhinitis).
  • Butterbur has not been proven to be helpful for allergic skin reactions or asthma.

Butterbur Safety

  • The raw, unprocessed butterbur plant contains chemicals called pyrrolizidine alkaloids (PAs). PAs can cause liver damage and can result in serious illness. Only butterbur products that have been processed to remove PAs and are labeled or certified as PA-free should be used.
  • Several studies, including a few studies of children and adolescents, have reported that PA-free butterbur products are safe and well tolerated when taken by mouth in recommended doses for up to 16 weeks. The safety of longer-term use has not been established.
  • Butterbur is usually well tolerated but can cause side effects such as belching, headache, itchy eyes, diarrhea, breathing difficulties, fatigue, and drowsiness.
  • Butterbur may cause allergic reactions in people who are sensitive to plants such as ragweed, chrysanthemums, marigolds, and daisies.
  • Butterbur should only be given to children under the supervision of a qualified health practitioner.

Butterbur References

 

PubMed Articles About


Source: National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] – [cited 2018 Apr 5]. Available from: https://www.ncbi.nlm.nih.gov/

Wang, CX., Wu, D., Yang, PP., Wu, QH., (2020) [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].

We aimed to compare the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonist (VKA) in the prevention and treatment of thrombotic diseases in patients with active cancer. To find randomized controlled trials (RCT) in which NOACs were compared VKAs in active cancer, we searched the electronic databases (PubMed, Web of Science and Clinical Trials) up to May 2019 and and languages restricted to Chinese and English. According to the screening strategy, two researchers independently screened and extracted literature, evaluated the quality of literature, the suitability of collected cross study data for analysis, and tested the heterogeneity. The relative risk () and 95% confidence interval (95%) of major bleeding, clinically related non-major bleeding, VTE, stroke and all-cause mortality in active cancer patients with VTE, active cancer patients with non-valvular atrial fibrillation (NVAF) was calculated and the results were compared between NOAC with VKA. A total of 9 RCTs were included, including 5 cancers with VTE (5/9) and 4 cancers with NVAF (4/9). A total of 5 867 patients were included. After excluding 1 818 (30.99%) patients with cancer history, 4 049 (68.86%) patients with active cancer were statistically analyzed. Among them, 2 278 (56.26%) received NOAC treatment, 1 771 patients (43.74%) received VKA treatment. The quality of the included documents was high (all scores were>5 points), and the data of each included document could be summarized and analyzed (>0.05). The heterogeneity of main outcome events was very low ( = 0). In VTE patients with active cancer, NOACs were more effective in reducing recurrence of VTE (=0.55, 95% 0.36 -0.84; 0.005) and clinically related non-major bleeding (=0.77, 95% 0.60 -0.98; 0.03) than VKAs. In NVAF patients with active cancer, efficacy of NOACs and VKAs was similar in terms of reducing VTE, stroke, clinically related non-major bleeding, major bleeding and all-cause mortality events (>0.05). For patients with active cancer accompanied by VTE, NOAC may has more advantages in efficacy and safety compared to VKA in the prevention and treatment of thrombotic diseases.

Zhang, ZD., Liu, H., Lyu, J., Yu, DD., Sun, MH., (2020) [Systematic review and Meta-analysis of efficacy and safety of Xiangsha Yangwei Pills in treatment of chronic gastritis].

To systematically evaluate the efficacy and safety of Xiangsha Yangwei Pills in the treatment of chronic gastritis. Compu-ter retrieval was performed for Cochrane Library, Medline, EMbase, China Knowledge Network Database(CNKI), China Biomedical Literature Service System(SinoMed), Chongqing Weipu Chinese Science and Technology Journal Database(VIP) and WanFang Database(WanFang) randomized controlled trials about Xiangsha Yangwei Pills combined with Western medicine in the treatment of chro-nic gastritis. The retrieval time ranged from the establishment of the library to April 26, 2019. Meta-analysis was performed by RevMan 5.3 software after two independent researchers conducted literature screening, data extraction and quality evaluation according to inclusion and exclusion criteria. A total of 1 720 patients were enrolled in 18 RCT. According to the classification of chronic gastritis, they were divided into three subgroups: chronic gastritis, chronic atrophic gastritis and chronic superficial gastritis. The results of Meta-ana-lysis showed that the efficacy of Xiangsha Yangwei Pills combined with Western medicine in treating chronic gastritis was higher than that of Western medicine. As for the recurrence rate, Xiangsha Yangwei Pills combined with Western medicine was lower than Western medicine. And there was no statistical difference about helicobacter pylori(Hp) eradication rate between Xiangsha Yangwei Pills combined with Western medicine as well as Western medicine. In terms of the incidence of adverse reactions, Xiangsha Yangwei Pills combined with Western medicine was lower than Western medicine, and no serious adverse reaction was reported. The results of this systematic review showed that compared with the conventional Western medicine group, Xiangsha Yangwei Pills combined with Western medicine can significantly alleviate clinical symptoms of chronic gastritis, with fewer adverse reactions. However, due to the low methodological quality of the included studies and the reliability of the impact conclusions, high-quality multi-center, large-sample, randomized, double-blind controlled trials are needed for validation.

Clifford, T., Jeffries, O., Stevenson, EJ., Davies, KAB., (2020) The effects of vitamin C and E on exercise-induced physiological adaptations: a systematic review and Meta-analysis of randomized controlled trials.

We conducted a systematic review and meta-analysis of randomized controlled trials examining the effect of vitamin C and/or E on exercise-induced training adaptations. Medline, Embase and SPORTDiscus databases were searched for articles from inception until June 2019. Inclusion criteria was studies in adult humans where vitamin C and/or E had to be consumed alongside a supervised exercise training program of ≥4 weeks. Nine trials were included in the analysis of aerobic exercise adaptations and nine for resistance training (RT) adaptations. Vitamin C and/or E did not attenuate aerobic exercise induced improvements in maximal aerobic capacity (O (SMD -0.14, 95% CI: -0.43 to 0.15,  = 0.35) or endurance performance (SMD -0.01, 95% CI: -0.38 to 0.36,  = 0.97). There were also no effects of these supplements on lean mass and muscle strength following RT (SMD -0.07, 95% CI: -0.36 to 0.23,  = 0.67) and (SMD -0.15, 95% CI: -0.16 to 0.46,  = 0.35), respectively. There was also no influence of age on any of these outcomes ( > 0.05). These findings suggest that vitamin C and/or E does not inhibit exercise-induced changes in physiological function. Studies with larger sample sizes and adequate power are still required.

Chen, G., Chen, Y., Chen, Z., Gao, S., Zhang, P., Zhang, H., Huang, Y., Lin, Y., Wei, L., (2021) Sanao decoction for asthma: Protocol of a systematic review.

Asthma is a chronic inflammatory disease characterized by recurrent attacks of breathlessness and wheezing, which often worsen at night or in the early morning and vary from person to person in severity and frequency. Sanao decoction (SAD), as a traditional Chinese medicine compound, has a long history of clinical application in the treatment of respiratory diseases. Whereas neither systematic nor meta-analysis of randomized controlled articles explain the efficacy of SAD in treating asthma. Therefore, we provide a protocol to evaluate the efficacy and safety of SAD for asthma.

Ahmad, I., Zaman, GS., Silvian, SP., Alshaharani, MS., Ahmad, I., Mansuri, N., Fayazuddin, S., (2021) Resistance training exercises for obese and non-obese individuals living in high-altitude regions utilizing biochemical markers-A controlled trial.

High-altitude disease prevalence varies according to types of exposure and the effects of hypoxic and hypobaric environments, with the result that people at high altitudes present many different physiological responses.